Perils of Evidence-Based Medicine
暂无分享,去创建一个
[1] W. W. Rozeboom. The fallacy of the null-hypothesis significance test. , 1960, Psychological bulletin.
[2] D. Bakan,et al. The test of significance in psychological research. , 1966, Psychological bulletin.
[3] D. Bamber. The area above the ordinal dominance graph and the area below the receiver operating characteristic graph , 1975 .
[4] R. Kronmal,et al. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. , 1992, Journal of the American College of Cardiology.
[5] D. Nelson,et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. , 1993, Journal of the National Cancer Institute.
[6] W. Curran,et al. Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. , 1998, International journal of radiation oncology, biology, physics.
[7] M J Gleason,et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] L. Zamorano,et al. Use of the RTOG recursive partitioning analysis to validate the benefit of iodine-125 implants in the primary treatment of malignant gliomas. , 1999, International journal of radiation oncology, biology, physics.
[9] D. Osoba,et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse , 2000, British Journal of Cancer.
[10] M. Chamberlain,et al. Medical Research Council adjuvant trial in high-grade gliomas. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] M. member. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a medical research council trial. , 2001 .
[12] David M. Thomas,et al. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] J. Olson,et al. The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. , 2002, Neurosurgery.
[14] The Use of Frailty Hazard Models for Unrecognized Heterogeneity That Interacts with Treatment: Considerations of Efficiency and Power , 2002, Biometrics.
[15] J. Karlawish,et al. The continuing unethical conduct of underpowered clinical trials. , 2002, JAMA.
[16] M. Prados,et al. Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404. , 2004, International journal of radiation oncology, biology, physics.
[17] Robyn Bluhm,et al. From Hierarchy to Network: a richer view of evidence for evidence-based medicine , 2005, Perspectives in biology and medicine.
[18] R. Mirimanoff,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[19] P. Killeen,et al. An Alternative to Null-Hypothesis Significance Tests , 2005, Psychological science.
[20] J. Grossman,et al. The Randomized Controlled Trial: gold standard, or merely standard? , 2005, Perspectives in biology and medicine.
[21] R. Mirimanoff,et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.
[22] P. Loehrer. Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma , 2006 .
[23] Denis Lacombe,et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Walter Curran,et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] A. Fortin,et al. Antioxidant vitamins supplementation and mortality: A randomized trial in head and neck cancer patients , 2006, International journal of cancer.
[26] S. Mouly,et al. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. , 2006, Archives of internal medicine.
[27] Nancy Cartwright,et al. Are RCTs the Gold Standard? , 2007 .
[28] A. Fortin,et al. Interaction between antioxidant vitamin supplementation and cigarette smoking during radiation therapy in relation to long‐term effects on recurrence and mortality: A randomized trial among head and neck cancer patients , 2007, International journal of cancer.
[29] B. Scheithauer,et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for pure and mixed anaplastic oligodendrogliomas: Radiation therapy oncology group trial 9402. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] Maya J Goldenberg,et al. Iconoclast or Creed?: Objectivism, Pragmatism, and the Hierarchy of Evidence , 2009, Perspectives in biology and medicine.
[31] Kirstin Borgerson,et al. Valuing Evidence: Bias and the Evidence Hierarchy of Evidence-Based Medicine , 2009, Perspectives in biology and medicine.
[32] B. Theeler,et al. High-Grade Gliomas , 2011, Current treatment options in neurology.
[33] D. Petrač. Antiarrhythmic drugs for maintaining of sinus rhythm , 2011 .